Azienda Ospedaliera Universitaria Senese
- Address
- Strada Delle Scotte 14, 53100 Siena, Italy
Oncology and Immunotherapy
At Azienda Ospedaliera Universitaria Senese, clinical research in neoplasms focuses on difficult-to-treat cancers such as advanced melanoma, metastatic or unresectable melanoma, Merkel cell carcinoma, and advanced non-small cell lung cancer with KRAS G12C mutation. These studies are exploring new treatment strategies and combinations to improve outcomes for patients with limited options.
- Testing new immunotherapy approaches for melanoma and Merkel cell carcinoma
- Evaluating combination treatments for advanced NSCLC with KRAS G12C mutation
- Assessing treatment effectiveness in cancers resistant to prior therapy
This research reflects a strong interest in improving cancer care through innovative immune-based therapies and targeted treatment combinations.
Infectious Diseases
The site also contributes to studies in bacterial infections and mycoses, with a focus on serious fungal diseases such as candidemia and invasive candidiasis. The goal is to compare new antifungal treatment approaches with established care to find safer and more effective options for adults with severe infection.
- Developing improved treatment options for candidemia and invasive candidiasis
- Comparing a new antifungal therapy with standard treatment
- Supporting better management of serious fungal bloodstream infections
This area highlights the hospital’s role in advancing care for complex infectious diseases where timely and effective treatment is especially important.
Cardiovascular Research
In cardiovascular diseases, research is centered on heart failure with mildly reduced or preserved ejection fraction, particularly in patients who also have systemic inflammation. These trials are examining whether new anti-inflammatory treatment strategies can lower the risk of serious heart-related events and improve long-term outcomes.
- Studying therapies for heart failure with HFmrEF and HFpEF
- Evaluating whether reducing inflammation can improve cardiovascular outcomes
- Testing new approaches to prevent cardiovascular death and worsening heart failure
This research area shows a clear focus on improving treatment for patients with chronic heart failure and related inflammatory risk.
Skin and Connective Tissue Diseases
The skin and connective tissue diseases portfolio includes studies in advanced melanoma, where investigators are assessing new combinations and administration methods to better support treatment delivery and effectiveness. These efforts aim to refine how modern cancer therapies are used in everyday care.
- Exploring new ways to deliver melanoma treatment
- Assessing whether treatment combinations can improve control of advanced disease
- Supporting better options for patients with advanced skin cancer
At Azienda Ospedaliera Universitaria Senese, this field connects dermatologic oncology with broader efforts to improve outcomes in aggressive skin cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 25 therapeutic areas and 15 of 366 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 343 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 74 by active trials.
lock +73 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC17trials
lock +32 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Senese
lock Showing 1 of 226 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN". | Fondazione Radioterapia Oncologica Onlus | Phase II | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 366 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 34 | Unknown | 2015-07-16 | 2026-03-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
